Oncorus Past Earnings Performance

Past criteria checks 0/6

Oncorus's earnings have been declining at an average annual rate of -25.8%, while the Biotechs industry saw earnings growing at 17.8% annually.

Key information

-25.8%

Earnings growth rate

67.9%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	-290.9%
Net Margin	n/a
Last Earnings Update	31 Mar 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Oncorus makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:ONCR Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
31 Mar 23	-91	29	45
31 Dec 22	-77	30	47
30 Sep 22	-76	29	46
30 Jun 22	-73	29	44
31 Mar 22	-70	29	41
31 Dec 21	-65	26	38
30 Sep 21	-57	24	33
30 Jun 21	-62	16	32
31 Mar 21	-59	14	28
31 Dec 20	-57	11	26
30 Sep 20	-57	11	24
30 Jun 20	-43	10	23
31 Mar 20	-38	9	23
31 Dec 19	-35	8	23
31 Dec 18	-18	7	11

Quality Earnings: ONCR is currently unprofitable.

Growing Profit Margin: ONCR is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ONCR is unprofitable, and losses have increased over the past 5 years at a rate of 25.8% per year.

Accelerating Growth: Unable to compare ONCR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ONCR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).

Return on Equity

High ROE: ONCR has a negative Return on Equity (-290.93%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/01/03 16:17
End of Day Share Price	2023/12/29 00:00
Earnings	2023/03/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncorus, Inc. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Matthew Barcus	Chardan Capital Markets, LLC
Joshua Schimmer	Evercore ISI
Swayampakula Ramakanth	H.C. Wainwright & Co.

Oncorus Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

Oncorus, Inc. Files Form 15

Nasdaq to Delist the Common Stock of Oncorus

Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index

Oncorus Receives Written Notice from The Nasdaq Stock Market LLC Regarding in Light of the Plan of Dissolution

Oncorus Announces Management Changes

Oncorus, Inc. Announces Workforce Reduction Plan

Oncorus, Inc. Appoints Alexander Nolte as Principal Accounting Officer

Oncorus, Inc. announced delayed 10-Q filing

Nasdaq Grants Oncorus an Additional 180 Calendar Days, or Until October 30, 2023, to Regain Compliance with the Minimum Closing Bid Price

Oncorus, Inc. Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Oncorus, Inc. Announces the Presentation of Preclinical Data for ONCR-719 in A Poster At the 2022 Society for Neuro-Oncology Annual Meeting

Price target decreased to US$5.75

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

Now 23% undervalued

Oncorus GAAP EPS of -$0.74 misses by $0.02

Oncorus, Inc. Appoints Douglas Fambrough to Board of Directors

Oncorus, Inc., Annual General Meeting, Jun 22, 2022

Oncorus, Inc. Announces the Appointment of Richard Wanstall as Chief Financial Officer

Price target decreased to US$17.00

Oncorus, Inc. Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting

Oncorus, Inc. announced that it expects to receive $45 million in funding from K2 HealthVentures

Oncorus, Inc. Promotes John Goldberg to Chief Medical Officer

President exercised options to buy US$184k worth of stock.

COO & Chief of Staff recently bought US$174k worth of stock

Price target decreased to US$34.75

President exercised options to buy US$469k worth of stock.

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic

Oncorus, Inc.(NasdaqGM:ONCR) dropped from Russell 3000E Growth Index

Independent Director Robert Kirkman has left the company

Independent Director Cameron Wheeler has left the company

Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788

Insider exercised options to buy US$590k worth of stock.

Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans

Independent Director has left the company

Oncorus Anticipates Reporting Interim Data from its Ongoing Phase 1 Clinical Trial of its Lead oHSV-Based Clinical Candidate ONCR-177 in Patients with Solid Tumor Indications in the Second Half of 2021

What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?

New 90-day low: US$20.97

Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels

Oncorus, Inc. Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical Stage Oncolytic Herpes Simplex Viral Immunotherapy Product Candidate ONCR-177

New 90-day high: US$35.55

Oncorus to build viral immunotherapy clinical manufacturing facility in U.S.